Abstract
Multiple Sclerosis is the most common non-traumatic disorder of the central nervous system and is generally regarded as an immune-mediated disorder that occurs in young adults. Since cerebrospinal fluid is in close contact with the extracellular surface of the brain, it is of great interest to examine possible biomarkers for multiple sclerosis. Proteomic studies of cerebrospinal fluid samples represent an important step towards a better understanding of the disease and may lead to the identification of clinically useful markers. Methodological advances in proteomics allowed the comparison of the protein content in different cerebrospinal fluid samples, using gel or liquid-based approaches coupled with mass spectrometry. In this paper, we discuss the advantages and limitations of the strategies employed and the potential biomarkers for multiple sclerosis identified so far using proteomics-based approaches.
Keywords: Multiple sclerosis, cerebrospinal fluid, biomarkers, proteomics, inflammatory demyelinating disease, autoimmune aetiology, heterogeneity, inflammation, neuronal lesions, magnetic resonance imaging, neurodegenerative disorders, homeostasis, mass spectrometry, gel-free techniques, proteomics-based technologies
Current Molecular Medicine
Title: Proteomics-Based Technologies in the Discovery of Biomarkers for Multiple Sclerosis in the Cerebrospinal Fluid
Volume: 11 Issue: 4
Author(s): A. S.T. Lourenco, I. Baldeiras, M. Graos and C. B. Duarte
Affiliation:
Keywords: Multiple sclerosis, cerebrospinal fluid, biomarkers, proteomics, inflammatory demyelinating disease, autoimmune aetiology, heterogeneity, inflammation, neuronal lesions, magnetic resonance imaging, neurodegenerative disorders, homeostasis, mass spectrometry, gel-free techniques, proteomics-based technologies
Abstract: Multiple Sclerosis is the most common non-traumatic disorder of the central nervous system and is generally regarded as an immune-mediated disorder that occurs in young adults. Since cerebrospinal fluid is in close contact with the extracellular surface of the brain, it is of great interest to examine possible biomarkers for multiple sclerosis. Proteomic studies of cerebrospinal fluid samples represent an important step towards a better understanding of the disease and may lead to the identification of clinically useful markers. Methodological advances in proteomics allowed the comparison of the protein content in different cerebrospinal fluid samples, using gel or liquid-based approaches coupled with mass spectrometry. In this paper, we discuss the advantages and limitations of the strategies employed and the potential biomarkers for multiple sclerosis identified so far using proteomics-based approaches.
Export Options
About this article
Cite this article as:
S.T. Lourenco A., Baldeiras I., Graos M. and B. Duarte C., Proteomics-Based Technologies in the Discovery of Biomarkers for Multiple Sclerosis in the Cerebrospinal Fluid, Current Molecular Medicine 2011; 11 (4) . https://dx.doi.org/10.2174/156652411795677981
DOI https://dx.doi.org/10.2174/156652411795677981 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mechanisms of Melatonin in Alleviating Alzheimer’s Disease
Current Neuropharmacology Molecular Hydrogen Application in Stroke: Bench to Bedside
Current Pharmaceutical Design Green Synthesis of Phosphoryl-2-Oxo-2H-Pyran via Three Component Reaction of Trialkyl Phosphites
Combinatorial Chemistry & High Throughput Screening A Role for Calcineurin in Alzheimers Disease
Current Neuropharmacology The Potential Therapeutic Role of the HMGB1-TLR Pathway in Epilepsy
Current Drug Targets Magnetic Nanoparticles in Brain Disease Diagnosis and Targeting Drug Delivery
Current Nanoscience Recent Knowledge on Medicinal Plants as Source of Cholinesterase Inhibitors for the Treatment of Dementia
Mini-Reviews in Medicinal Chemistry Parkinson's Disease: From Genetics to Clinical Practice
Current Genomics The Renin-Angiotensin System in the Mammalian Central Nervous System
Current Protein & Peptide Science Araucaria Angustifolia: A Potential Nutraceutical with Antioxidant and Antimutagenic Activities
Current Nutrition & Food Science Therapeutic Strategies for the Treatment of Spinal Muscular Atrophy (SMA) Disease
Current Genomics Peripheral Immunity, Immunoaging and Neuroinflammation in Parkinson’s Disease
Current Medicinal Chemistry Ascorbic Acid: Its Role in Immune System and Chronic Inflammation Diseases
Mini-Reviews in Medicinal Chemistry RAGE: A Single Receptor for Several Ligands and Different Cellular Responses: The Case of Certain S100 Proteins
Current Molecular Medicine The Endocannabinoid System May Modulate Sleep Disorders in Aging
Current Neuropharmacology Instructions from the Vascular System - Directing Neural Stem Cell Fate in Health and Disease
Current Medicinal Chemistry Ischemic Neuronal Damage
Current Pharmaceutical Design Editorial (Thematic Issue: Therapeutic Applications of Advanced Drug Delivery Systems)
Current Pharmaceutical Design BACE1 Structure and Function in Health and Alzheimers Disease
Current Alzheimer Research The Role of Toll-Like Receptors in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: A New Promising Therapeutic Approach?
CNS & Neurological Disorders - Drug Targets